Abstract: A method of treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies is described. A carbonic Anhydrase 1 (CA1) inhibitor is used in a method for treating or preventing a myeloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis. The carbonic Anhydrase 1 is also used as a biomarker for myeloproliferative disorders and other hematopoietic malignancies, and as a biomarker of the efficacy of compounds for treating or preventing these conditions.

Abstract: The invention relates to methods for predicting the outcome of a patient suffering from prostate cancer or breast cancer and methods for the treatment of prostate cancer or breast cancer. The inventors show that Doublecortin-expressing (DCX+) neural precursors from the central nervous system (CNS) enter the bloodstream, infiltrate prostate tumours and metastasis and differentiate into neo-neurons that contribute to tumour development. In human primary prostate tumours and transgenic mouse cancer tissues, the density of DCX+ neural progenitors is strongly associated with tumour aggressiveness, invasion and recurrence. In transgenic cancer mice, oscillations of DCX+ neural stem cells in the subventricular zone (SVZ), a neurogenic area of the CNS, were associated with egress of DCX+ cells from the SVZ to the bloodstream. These cells then reach the tumour where they initiate neurogenesis.

Abstract: The present invention relates to the prevention or treatment of inflammatory diseases. The present invention also relates to a method for screening a compound capable of promoting or restoring the resolution of inflammation and which may be useful for preventing or treating inflammatory disorders.